At the crossroads of cancer;Au carrefour du cancer

Bulletin du Cancer

Volumn 100, Issue 6, 2013, Pages 569-574

  Chouaib, Salem ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Cancer vaccine; Immunotherapy; Tumor immunology; Tumor microenvironment

Indexed keywords

CANCER CONTROL; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER THERAPY; IMMUNE SYSTEM; IMMUNOSURVEILLANCE; NEOPLASM; PLASTICITY; REVIEW; TUMOR CELL; TUMOR MICROENVIRONMENT;

EID: 84880210763     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2013.1754     Document Type: Article

References (34)

1. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004 ; 21 : 137- 48.
2. Rey J, Olive D, Sebahoun G, O'Callaghan T, Costello RT. New insights into cytotoxic effector cells. Bull Cancer 2005 ; 92 : s935-43.
3. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006 ; 313 : 1960-4.
4. Tartour E, Mathiot C, Fridman WH. Current status of interleukin- 2 therapy in cancer. Biomed Pharmacother 1992 ; 46 : 473-84 (Review).
5. Shizuru JA, Jerabek L, Edwards CT, Weissman IL. Transplantation of purified hematopoietic stem cells: requirements for overcoming the barriers of allogeneic engraftment. Biol Blood Marrow Transplant 1996 ; 2 : 3-14
6. (erratum in: Biol Blood Marrow Transplant 1997 ; 3 : 50).
7. Spiess PJ, Yang JC, Rosenberg SA. In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin- 2. J Natl Cancer Inst 1987 ; 79 : 1067-75.
8. Whiteside TL. Cancer therapy with tumor-infiltrating lymphocytes: evaluation of potential and limitations. In Vivo 1991 ; 5 : 553-9.
9. Dotti G. Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?". Hum Gene Ther 2009 ; 20 : 1229-39. doi: 10.1089/hum.2009.142 (published online 2009 September 22).
10. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor - Modified T cells for acute lymphoid leukemia. N Engl J Med 2013 ; 368 : 1509-18.
11. Porter DL, Kalos M, Zheng Z, Levine B, June C. Chimeric antigen receptor therapy for B-cell malignancies. J Cancer 2011 ; 2 : 331-2 (Short report).
12. Bennasroune A, Gardin A, Aunis D, Crémel G, Hubert P. Tyrosine kinase receptors as attractive targets of cancer therapy. Crit Rev Oncol Hematol 2004 ; 50 : 23-38.
13. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002 ; 99 : 754-8.
14. Chen HX, Gore-Langton RE, Cheson BD. Clinical trials referral resource: current clinical trials of the anti-VEGF monoclonal antibody bevacizumab. Oncology (Williston Park) 2001 ; 15 : 1017, 1020, 1023-6.
15. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011 ; 480 : 480-9.
16. Voskens CJ, Goldinger SM, Loquai C, et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One 2013 ; 8 : e53745.
17. Ascierto PA, Simeone E, Sznol M, Fu YX, Melero I. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol 2010 ; 37 : 508-16.
18. Lurquin C, van Pel A, Mariamé B, et al. Structure of the gene of tum-transplantation antigen P91A: the mutated exon encodes a peptide recognized with Ld by cytolytic T cells. Cell 1989 ; 58 : 293- 303.
19. van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991 ; 254 : 1643-7.
20. Boon T, Coulie PG, van den Eynde B. Tumor antigens recognized by T cells. Immunol Today 1997 ; 18 : 267-8 (Review).
21. Gjertsen MK, Saeterdal I, Thorsby E, Gaudernack G. Characterisation of immune responses in pancreatic carcinoma patients after mutant p21 ras peptide vaccination. Br J Cancer 1996 ; 74 : 1828-33.
22. Linard B, Bézieau S, Benlalam H, et al. A ras-mutated peptide targeted by CTL infiltrating a human melanoma lesion. J Immunol 2002 ; 168 : 4802-8.
23. Gedde-Dahl 3rd. T, Eriksen JA, Thorsby E, Gaudernack G. T-cell responses against products of oncogenes: generation and characterization of human T-cell clones specific for p21 ras-derived synthetic peptides. Hum Immunol 1992 ; 33 : 266-74.
24. Gjertsen MK, Buanes T, Rosseland AR, et al. Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer 2001 ; 92 : 441-50.
25. Brichard V, van Pel A, Wölfel T, et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993 ; 178 : 489-95.
26. Coulie PG, Brichard V, van Pel A, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1994 ; 180 : 35-42.
27. Khanna R, Burrows SR, Nicholls J, Poulsen LM. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertyperestricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes. Eur J Immunol 1998 ; 28 : 451-8.
28. Tindle RW. Human papillomavirus vaccines for cervical cancer. Curr Opin Immunol 1996 ; 8 : 643-50 (Review).
29. Rosenberg SA. Shedding light on immunotherapy for cancer. N Engl J Med 2004 ; 350 : 1461-3.
30. Mocellin S, Mandruzzato S, Bronte V, Lise M, Nitti D. Part I: vaccines for solid tumours. Lancet Oncol 2004 ; 5 : 681-9.
31. Chouaib S. Integrating the quality of the cytotoxic response and tumor susceptibility into the design of protective vaccines in tumor immunotherapy. J Clin Invest 2003 ; 111 : 595-7.
32. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011 ; 331 : 1565-70.
33. Chouaib S, Messai Y, Couve S, Escudier B, Hasmim M, Noman MZ. Hypoxia promotes tumor growth in linking angiogenesis to immune escape. Front Immunol 2012 ; 3 : 21.
34. Noman MZ, Messai Y, Carré T, et al. Microenvironmental hypoxia orchestrating the cell stroma cross talk, tumor progression and antitumor response. Crit Rev Immunol 2011 ; 31 : 357-77 (Review).